During the pandemic, Dimerix (DXB: $0.17) was very pleased to have been able to complete two Phase II kidney disease studies. The company has now moved to a Phase III program in FSGS (kidney disease) involving 75 sites spread across 12 countries, including in the US where the company recently gained FDA approval (IND) to commence its study there as well. The first patient was treated in this study this week.
Dimerix CEO Nina Webster said that sclerotic kidney disease is a progressive three mechanism cycle that results in an acceleration of the disease as it progresses to end stage kidney failure. The drugs currently on the market all focus on the first mechanism of this disease by reducing hypertension across the bloodstream.